Dergiler / Eurasian Journal of Medicine / 2020 / Cilt: 52 - Sayı: 2

Paraoxonase Activity and Phenotype Distribution in Patients with Chronic Obstructive Pulmonary Disease

Sayfa
161–165
Yayın Tarihi
2022-10-18
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

We also found that smoking (95.0% CI: 0.001-0.036, p

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objective: Paraoxonase 1 (PON1) and arylesterase (ARE) enzymes have an important role in the prevention of oxidative stress which is related to the pathogenesis of chronic obstructive pulmonary disease (COPD).
📊
Temel Bulgular & Veri:PON1 levels vary widely among individuals and ethnic groups, which is in part associated with polymorphisms.Materials and Methods: We investigated PON1 and ARE activity and phenotype distribution in COPD patients and healthy individuals.
💡
Sonuç & Katkı:We also found that smoking (95.0% CI: 0.001-0.036, p
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Objective: Paraoxonase 1 (PON1) and arylesterase (ARE) enzymes have an important role in the prevention of oxidative stress which is related to the pathogenesis of chronic obstructive pulmonary disease (COPD). PON1 levels vary widely among individuals and ethnic groups, which is in part associated with polymorphisms.Materials and Methods: We investigated PON1 and ARE activity and phenotype distribution in COPD patients and healthy individuals. Sixty six COPD patients and 59 control subjects were involved in the study. Serum PON1 and ARE activities were detected by spectrophotometric method. The ratio of salt-induced PON1 to ARE activity was used to determine phenotypes as QQ, QR, and RR.Results: COPD patients exhibited higher PON1 activity (199.1 vs 129.2, p=0.002) but lower ARE activity compared to control (21.3 vs 33.5, p=0.021). There was a significant difference between COPD and control group with respect to PON1 phenotype characteristics. RR phenotypic distribution was more common in the COPD group than in control (60.6% [95% CI: 48.8 - 72.3] versus 22.0 % [95% CI: 12.0 - 31.9], p=0.001). We also found that smoking (95.0% CI: 0.001-0.036, p

🔖

Bu Makaleye Atıf Yap

ÇEVİK, C., SARIOĞLU, N., BİLEN, Ç., GENCER, N. (2022). Paraoxonase Activity and Phenotype Distribution in Patients with Chronic Obstructive Pulmonary Disease. Eurasian Journal of Medicine, Cilt: 52 - Sayı: 2, 161–165. https://ajindex.com/articles/508884

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (4)

  1. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2016 Report. Available from: URL:
  2. Barnes PJ. Inflammatory mechanisms in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol 2016; 138: 16-27. [Crossref] 3. Siafakas N, Corlateanu A, Fouka E. Phenotyping before starting treatment in COPD? COPD 2017; 14: 367-74. [Crossref] 4. Fragoso E, André S, Boleo-Tomé JP, et al. Understanding COPD: A vision on phenotypes, comorbidities and treatment approach. Rev Port Pneumol 2016; 22: 101-11. [Crossref] 5. Kappelle PJ, de Boer JF, Perton FG, et al. Increased LCAT activity and hyperglycaemia decrease the antioxidative functionality of HDL. Eur J Clin Invest 2012; 42: 487-95. [Crossref] 6. Sarioglu N, Hismiogullari AA, Erel F, et al. Paraoxonase 1 Phenotype and Paraoxonase Activity in Asthmatic Patients. Iran J Allergy Asthma Immunol 2015; 14: 60-6
  3. Rumora L, Rajković MG, Kopčinović LM, et al. Paraoxonase 1 activity in patients with Chronic Obstructive Pulmonary Disease. COPD 2014; 11: 539-45. [Crossref] 8. Wysocka A, Cybulski M, Berbeć H, et al. Dynamic changes of paraoxonase 1 activity towards paroxon and phenyl acetate during coronary artery surgery. BMC Cardiovasc Disord 2017; 17: 92. [Crossref] 9. Rodríguez-Esparragón F, Rodríguez-Pérez JC, Hernández-Trujillo Y, et al. Allelic variants of the Human Scavenger Receptor Class B Type 1 and Paraoxonase 1 on Coronary Heart Disease-Genotype-Phenotype Correlations. Arterioscler Thromb Vasc Biol 2005; 25: 854-60. [Crossref] 10. Eckerson HW, Romson J, Wyte C, et al. The human serum paraoxonase polymorphism: identification of phenotypes by their response to salts. Am J Hum Genet 1983; 35: 214-27
  4. Costa LG, Vitalone A, Cole TB, et al. Modulation of paraoxonase (PON1) activity. Biochem Pharmacol 2005; 69: 541-50. [Crossref] 12. Richter RJ, Jarvik GP, Furlong, CE. Paraoxonase 1 (PON1) status and substrate hydrolysis. Toxicol Appl Pharmacol 2009; 235: 1-9. [Crossref] 13. Brophy VH, Hastings MD, Clendenning JB, et al. Polymorphisms in the human paraoxonase (PON1) promoter. Pharmacogenetics 2001; 11: 77-84. [Crossref] 14. Zinellu A, Fois AG, Sotgia S, et al. Plasma protein thiols: an early marker of oxidative stress in asthma and chronic obstructive pulmonary disease. Eur J Clin Invest 2016; 46: 181-8. [Crossref] 15. Bestall JC, Paul EA, Garrod R, et al. Usefulness of the Medical Research Counci